DON'T BUY
Not expensive, 10x earnings. Be careful with pharma, look at the pipeline. Focusing on one area, and that's the risk. Volatility as drugs come off patent. Lots of restructuring. He owns JNJ instead with its 3 businesses. Yield over 5%.
biotechnology / pharmaceutical

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
Unspecified
It has re-structured and is selling off some of its personal care business, thereby concentrating more on the pharmaceutical side. Not expensive and has a dividend yield over 6%.
biotechnology / pharmaceutical
BUY
They're spinning off their consumer products division, so GSK has historically traded at a discount with slower growth than other drugmakers. New management has turned around the pharmaceuticals side and make good consumer products. Aging populations in the west is a tailwind.
biotechnology / pharmaceutical
DON'T BUY
Large pharmaceutical company. Business model challenging since large investment required to produce new products. Good company, but owns other names in the space.
biotechnology / pharmaceutical
BUY
Options trading He jumped on some options. He likes healthcare and is adding to the sector. he doing call buying with Glaxo, not stock buying. There's a lot of activity here.
biotechnology / pharmaceutical
BUY
In 2018, they planned to merge their consumer health business with Pfizer's consumer to create a powerhouse, and planned to spin off this unit in three years. Last summer they offered an update--everyone expects a big cut to their 5% dividend yield, but cut it by only 31%. Management also offered encouraging sales projections. A hedge fund wants to bring in new leadership; he's unsure of this, but these types of move tend to prod management to deliver for shareholders, which is another reason to like this. He sees 10% upside.
biotechnology / pharmaceutical
BUY
Pays a 5% yield. It's doing okay. Okay to own for income.
biotechnology / pharmaceutical
DON'T BUY
A tough sector. Low growth, low PE, high dividend, pricing issues. Whole sector is struggling to come up with new drugs. Activist investor is probably pushing to break up the company; not good for long-term shareholders, though the share price would pop. Yield is about 6%.
biotechnology / pharmaceutical
COMMENT
The yield isn't safe. He truly wants GSK to do well and hopes their new vaccine with Sanopi works. Right now, GSK stock is up because of activists. Otherwise, shares will head down. He's less a fan of this now. Be prepared to take money off the table if the vaccine doesn't pan out.
biotechnology / pharmaceutical
BUY

Pharma has really not participated in rallies. In the last couple days, we have started to see some movement, like Pfizer. It is an area that will eventually be discovered. There is decent growth, nice dividends, but it lacks excitement. Nice to have one or two. It could be one of them.

biotechnology / pharmaceutical
HOLD
A big disappointment. He had hoped GSK could collaborate with another company on a vaccine, but he's been wrong. Sorry. Don't sell it with its 7% yield, but don't buy.
biotechnology / pharmaceutical
BUY
1-year outlook They've had a very good year like all pharmas, even in an election year. Pays a great yield and trades at a low multiple. Driving this are their COVID-19 vaccine efforts. They recently did a deal that puts them in MNRA which allows the fast-tracking of developing vaccines. This whole sector will continue to do well. The FDA has loosened rules to fast-track a COVID drug which he expects will lead to an effective result.
biotechnology / pharmaceutical
TOP PICK
A big player in vaccines and a top-10 pharma company in the world. The stock hasn't done much in the last 5 years, because drugs have come off patent. They're now the biggest consumer healthcare business in the world; they will spin off this company in two years. Pay a 5% yield that should rise this year. Vaccines and asthma meds will drive sales. (Analysts’ price target is $50.10)
biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Why bother with the U.K? The British stock market remains one of the strongest in the world and actually matched the TSX's performance in the 30 months after the pivotal June 2016 referendum (the FTSE fell off in 2019). Where to invest? Forget the British banks. They're already slumping, burdened by near-zero interest rates. Better to look at a long-term investment like GlaxoSmithKline (GSK), traded in New York as well as London. Robert Lauzon warns that a hard Brexit would pressure the UK pound and, by extension, GSK's bottom line, though he considers the pharma company fine overall with its dividend at 4.27% (New York) or 5.16% (London). GSK spun-off a US$12.7 billion consumer healthcare company with Pfizer to refocused on pharmaceuticals and growth. Paul McDonald views this is a likely long-term asset. Since September, four analysts have upgraded GSK, three of them to a buy. Like so many British stocks, GSK faces post-Brexit risk, but it's worth considering for the long run.
biotechnology / pharmaceutical
COMMENT

He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.

biotechnology / pharmaceutical
Showing 1 to 15 of 92 entries

GlaxoSmithKline PLC(GSK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 6

Stockchase rating for GlaxoSmithKline PLC is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

GlaxoSmithKline PLC(GSK-N) Frequently Asked Questions

What is GlaxoSmithKline PLC stock symbol?

GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N

Is GlaxoSmithKline PLC a buy or a sell?

In the last year, 6 stock analysts published opinions about GSK-N. 4 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for GlaxoSmithKline PLC.

Is GlaxoSmithKline PLC a good investment or a top pick?

GlaxoSmithKline PLC was recommended as a Top Pick by on . Read the latest stock experts ratings for GlaxoSmithKline PLC.

Why is GlaxoSmithKline PLC stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is GlaxoSmithKline PLC worth watching?

6 stock analysts on Stockchase covered GlaxoSmithKline PLC In the last year. It is a trending stock that is worth watching.

What is GlaxoSmithKline PLC stock price?

On 2022-12-02, GlaxoSmithKline PLC (GSK-N) stock closed at a price of $35.35.